UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana

PloS one, 2017-08, Vol.12 (8), p.e0183177-e0183177

2017

Volltextzugriff (PDF)

Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors

Vaccine, 2005-12, Vol.23 (50), p.5768-5774

2005

Volltextzugriff (PDF)

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate

Vaccine, 2019-07, Vol.37 (30), p.3957-3960

2019

Volltextzugriff (PDF)

LALF32‐51‐E7, a HPV‐16 therapeutic vaccine candidate, forms protein body‐like structures when expressed in Nicotiana benthamiana leaves

Plant biotechnology journal, 2018-02, Vol.16 (2), p.628-637

2018

Volltextzugriff (PDF)

LALF 32-51 -E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in Nicotiana benthamiana leaves

Plant biotechnology journal, 2018-02, Vol.16 (2), p.628-637

2018

Volltextzugriff (PDF)

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

Vaccine, 2011-01, Vol.29 (5), p.920-930

2011

Volltextzugriff (PDF)

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein Kinase 2 (casein Kinase 2)

Cancer research (Chicago, Ill.), 2004-10, Vol.64 (19), p.7127-7129

2004

Volltextzugriff (PDF)

LALF^sub 32-51^-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

Clinical & experimental metastasis, 2017-04, Vol.34 (3-4), p.241

2017

Volltextzugriff (PDF)

LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

Clinical & experimental metastasis, 2017-04, Vol.34 (3-4), p.241-249

2017

Volltextzugriff (PDF)

Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16

Journal of cellular immunotherapy, 2018-12, Vol.4 (2), p.71-74

2018

Volltextzugriff (PDF)

Congress of the European Society of Medical Oncology, ESMO, in Madrid, Spain, September 26 to 30, 2014

Biotecnología Aplicada, 2015-03, Vol.32 (1), p.1511-1512

Torrens, Isis

2015

Volltextzugriff (PDF)

Influence of Cell Disruption Methods on the Recovery and Immunogenicity of a Fusion Protein for a Therapeutic Cancer Vaccine Against HPV

Bioprocessing journal, 2016-01, Vol.14 (4), p.22-29

2016

Volltextzugriff (PDF)

LALF 32-51 -E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

Clinical & experimental metastasis, 2017-04, Vol.34 (3-4), p.241

2017

Volltextzugriff (PDF)

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

Journal of cellular immunotherapy, 2016-03, Vol.2 (1), p.44-51

2016

Volltextzugriff (PDF)

Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region

Journal of peptide science, 2010-01, Vol.16 (1), p.40

2010

Volltextzugriff (PDF)

Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF32-51 region

Journal of peptide science, 2010-01, Vol.16 (1), p.40-47

2010

Volltextzugriff (PDF)

Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen

SpringerPlus, 2013-01, Vol.2 (1), p.12-12, Article 12

2013

Volltextzugriff (PDF)

Identification of a novel antitumor peptide based on the screening of an Ala‐library derived from the LALF 32–51 region

Journal of peptide science, 2010-01, Vol.16 (1), p.40-47

2010

Volltextzugriff (PDF)

Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice

Angiogenesis (London), 2007-03, Vol.10 (1), p.23-34

2007

Volltextzugriff (PDF)

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia : First-in-Human, Proof-of-Concept Trial

ISRN obstetrics and gynecology, 2011-01, Vol.2011 (2011), p.1-9

2011

Volltextzugriff (PDF)

A novel strategy to improve antigen presentation for active immunotherapy in cancer. Fusion of the human papillomavirus type 16 E7 antigen to a cell penetrating peptide

Biotecnología Aplicada, 2012-09, Vol.29 (3), p.194-197

2012

Volltextzugriff (PDF)

Prevalence of Circulating Antibodies against a Streptokinase C-Terminal Peptide in Normal Blood Donors

Biochemical and biophysical research communications, 1999-09, Vol.263 (2), p.454-459

1999

Volltextzugriff (PDF)

A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic

Immunology letters, 1999-12, Vol.70 (3), p.213-218

1999

Volltextzugriff (PDF)

Mapping of the Antigenic Regions of Streptokinase in Humans after Streptokinase Therapy

Biochemical and biophysical research communications, 1999-05, Vol.259 (1), p.162-168

1999

Volltextzugriff (PDF)

A Mutant Streptokinase Lacking the C-Terminal 42 Amino Acids Is Less Reactive with Preexisting Antibodies in Patient Sera

Biochemical and biophysical research communications, 1999-12, Vol.266 (1), p.230-236

1999

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(27)

Sprache

Englisch
(24)
Portugiesisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Humans
(10)
Life Sciences & Biomedicine
(10)
Animals
(7)
Human Papillomavirus
(7)
Vaccines
(7)
Female
(6)
Mice
(6)
Proteins
(6)
Tumors
(6)
Biological And Medical Sciences
(5)
Cancer
(5)
Cervical Cancer
(5)
Fusion Protein
(5)
Immunotherapy
(5)
Mice, Inbred C57bl
(5)
Peptide Fragments - Immunology
(5)
Streptokinase
(5)
Biochemistry & Molecular Biology
(4)
Biotechnology & Applied Microbiology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana

Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate

LALF32‐51‐E7, a HPV‐16 therapeutic vaccine candidate, forms protein body‐like structures when expressed in Nicotiana benthamiana leaves

LALF 32-51 -E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in Nicotiana benthamiana leaves

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein Kinase 2 (casein Kinase 2)

LALF^sub 32-51^-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16

Congress of the European Society of Medical Oncology, ESMO, in Madrid, Spain, September 26 to 30, 2014

Influence of Cell Disruption Methods on the Recovery and Immunogenicity of a Fusion Protein for a Therapeutic Cancer Vaccine Against HPV

LALF 32-51 -E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region

Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF32-51 region

Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen

Identification of a novel antitumor peptide based on the screening of an Ala‐library derived from the LALF 32–51 region

Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia : First-in-Human, Proof-of-Concept Trial

A novel strategy to improve antigen presentation for active immunotherapy in cancer. Fusion of the human papillomavirus type 16 E7 antigen to a cell penetrating peptide

Prevalence of Circulating Antibodies against a Streptokinase C-Terminal Peptide in Normal Blood Donors

A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic

Mapping of the Antigenic Regions of Streptokinase in Humans after Streptokinase Therapy

A Mutant Streptokinase Lacking the C-Terminal 42 Amino Acids Is Less Reactive with Preexisting Antibodies in Patient Sera

Suchergebnisse filtern